South Africa is preparing to roll out a new HIV prevention injection, Lenacapavir, through its public healthcare system in early 2026. Touted as a potential game-changer in the fight against HIV, this injectable drug could significantly reduce new infections—particularly among high-risk groups—at a time when global funding for HIV programs is increasingly under strain.
According to Dr Joel Steingo of TB HIV Care, Lenacapavir may be a breakthrough tool in South Africa’s ongoing battle against HIV/AIDS. With global resources for HIV prevention becoming more limited, cost-effective and impactful solutions are more vital than ever.
“Lenacapavir has the potential to get the HIV epidemic back under control,” Steingo said.
“This can almost eliminate the chances of transmission of HIV.”
Steingo explained that Lenacapavir works similarly to antiretroviral therapy (ART), which is commonly used to treat HIV-positive individuals. However, when administered to HIV-negative individuals at high risk of exposure, Lenacapavir acts as a powerful shield, preventing the virus from taking hold—even if exposure occurs via sexual transmission or contact with infected blood.
How the New HIV Prevention Injection Lenacapavir Works
Unlike daily oral PrEP (pre-exposure prophylaxis), Lenacapavir is an injectable form of long-acting HIV prevention. It only needs to be administered twice a year, which could vastly improve adherence and reduce stigma associated with daily medication.
Many people, especially young women, sex workers, and members of the LGBTQ+ community, have expressed concerns over the visibility of daily HIV medication—often leading to non-compliance due to fear of judgment or misunderstanding.
“The injection is a really important option because it’s discreet,” Steingo noted.
“It doesn’t mean people are having to take a pill in front of their family where they might be judged or stigmatised.”
This privacy and convenience could make the new HIV prevention injection especially appealing in communities where stigma around HIV remains high.
The rollout of Lenacapavir is expected to prioritise individuals most at risk of contracting HIV. These include:
-
Adolescent girls and young women
-
Sex workers
-
Men who have sex with men
-
People who inject drugs
These groups often face social, economic, and structural barriers to consistent HIV prevention. Lenacapavir’s low-maintenance dosage schedule and private administration may offer a more accessible and sustainable solution.
South Africa continues to carry one of the world’s highest HIV burdens, with women aged 15–24 particularly affected. The new HIV prevention injection could be a powerful tool in reversing the trend, especially when integrated with broader sexual health and community support programs.
Another major advantage of Lenacapavir is its stability at room temperature—a feature that sets it apart from many other injectable or oral treatments that require refrigeration.
This makes Lenacapavir especially well-suited for rural or hard-to-reach areas, where maintaining cold storage can be challenging. For South Africa’s vast rural population, this small detail could make a big difference in access and effectiveness.
“This is one of the few injectable drugs that doesn’t need to be kept in a fridge,” said Steingo.
“That makes it much easier to roll out in areas without consistent electricity or access to refrigeration.”
He added that while South Africa’s public health system will need to strengthen logistics and training to handle the national rollout, the long-term benefits far outweigh the challenges.
Clinical trials for Lenacapavir—many of which took place in South Africa—have delivered highly encouraging results. The injection has demonstrated strong efficacy in preventing HIV infection, with minimal side effects and high acceptability among participants.
These findings have paved the way for global interest in Lenacapavir as a long-acting HIV prevention method, with several countries closely watching South Africa’s lead in its upcoming implementation.
The introduction of the new HIV prevention injection represents a potential turning point in South Africa’s HIV epidemic. While the nation has made considerable progress in expanding ART access and promoting HIV awareness, prevention remains a critical gap, particularly among youth and vulnerable populations.
Dr. Steingo remains optimistic:
“This injection could be a real game-changer. If we roll it out effectively, we can start seeing real reductions in new infections—possibly even ending the epidemic in our lifetime.”
With the scheduled rollout set for 2026, South Africa stands poised to lead the continent—and potentially the world—in a new chapter of HIV prevention and control.
Source- EWN
